Arvinas、辉瑞与Rigel于2026年6月11日获HSR批准达成许可协议 - 美国证券交易委员会文件披露

美股速递
Jun 17

根据一份提交给美国证券交易委员会的文件,生物技术公司Arvinas Holding Company LLC、制药巨头辉瑞以及Rigel Pharmaceuticals于2026年6月11日获得了《哈特-斯科特-罗迪诺反垄断改进法案》的批准。这一关键进展为各方推进此前宣布的许可协议扫清了监管障碍。

该协议的达成标志着相关合作进入了新的实质性阶段。获得HSR反垄断审查的通过,是此类涉及知识产权与市场准入的战略性合作中至关重要的一步。此举通常意味着监管机构认定该交易不会对相关市场的竞争构成实质性损害。

随着监管门槛的跨越,各方预计将加速执行许可协议的具体条款,推动相关研发或商业化项目的进展。这一动态受到行业观察者的密切关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10